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Dear editor: 1 
 few years after coming to the market, the first 
generation of oral contraceptive pills (OCPs) 
were linked to significant risk of venous throm-
boembolism (VTE). This increased risk was blamed on 
the presence of the estrogen-like compounds in these 
agents. Therefore, the efforts were initiated to decrease 
the VTE risk of OCPs by lowering the delivered estrogen 
content by adding progestins such as levonorgestrel to 
these products, which led to production of the second 
generation of OCPs. Thereafter, the third generation of 
these agents with lower doses of progesterone-like 
compounds with contraceptive efficacy was released. 
They contain the new progestins such as Drospirenone, 
Norgestimate, Desogestrel and Gestodene (1-3). 
Baratloo et al. review article (The Risk of Venous 
Thromboembolism with Different Generation of Oral 
Contraceptives) is a good systematic review of the cur-
rent evidence and concluded that taking second and 
third-generation OCPs increases the risk of VTE up to 3 
and 4.3 fold, respectively (4). Looking at the results of 
few other recent publications on the same subject re-
veals that risk of VTE from oral contraceptives is more 
significantly associated with both estrogen dose and 
duration of use rather than progesterone type. The saf-
est OCPs in terms of VTE are those containing levonorg-
estrel or norgestimate and the risk of VTE associated 
with desogestrel, drospirenone or cyproterone acetate 
containing OCPs is greater than that associated with 
OCPs containing levonorgestrel. It is important to note 
the increase in VTE due to third generation progestin 
pills was not associated with Norgestimate but the in-
creased risk was demonstrated with Desogestrel and 
Gestodene (5-8). 
The trend of this potentially lethal side effect of OCPs 
needs to be viewed in the light of two facts: 1) nowa-
days, the use of OCPs is not limited to contraception and 
we put patients on these medications for a plethora of 
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medical condition. On top of that, global socioeconomi-
cal changes has increased the number of women who 
have access to OCPs as well as the number of years 
these medications are taken continuously. 2) Our ad-
vances in technology has given us the chance to be able 
to diagnose (and sometimes over diagnose!) some med-
ical conditions such as VTE. This would certainly affect 
the way we look at the medications and their side ef-
fects. 
Nevertheless, OCPs, as an integral part of the modern 
medicine and today’s lifestyle, are not completely safe 
and to make them a safer choice for patients, the search 
is still on. 
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